Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

— PembroRad  

Official title:

A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02707588
• Other study ID #: GORTEC 2015-01
• Status: Completed
• Phase: Phase 2
• Start date: May 18, 2016
• Est. completion date: October 17, 2022

Study information

• Verified date: August 2022
• Source: Groupe Oncologie Radiotherapie Tete et Cou
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The general aim of the study is to evaluate the anti-tumour activity and the tolerance profile of Pembrolizumab + RT in comparison to cetuximab + RT in patients with locally advanced HNSCC and to explore potential correlations between treatment outcome and the immune landscape.

Description:

A majority of HNSCC are locally advanced and commonly treated with concomitant chemo-radiotherapy (CT-RT). However, a large proportion of patients with locally advanced stage are not suitable for receiving cisplatinum-based chemotherapy (CT) concomitant with radiotherapy (RT) either due to age, general and/or medical condition(s).

An alternative standard treatment has been established, combining RT and cetuximab.

However, both CT-RT and cetuximab-RT which are considered as standard approaches in locally advanced non operated HNSCC are associated with poor outcome in patients with the most advanced T stage (T4) and/or N stage (>=N2) and/or HPV negative tumours. A new and promising approach could target immune response.

Pembrolizumab is a high-affinity monoclonal anti-PD1 antibody which showed antitumor activity in melanoma and NSCLC. In the KEYNOTE-012 (multi-center, nonrandomized Phase Ib HNSCC), Pembrolizumab was well tolerated and safe with no serious drug related AEs reported. About 51% (26/51) of patients had decreased tumor burden which was seen both in HPV (-) and HPV(+) HNSCC.

This observation led to the hypothesis generated in the current study that Pembrolizumab is potentially a very active drug in HNSCC and that the combination of Pembrolizumab with radiotherapy will be well tolerated, given the very good toxicity profile of the drug and will improve the outcome of patients with locally advanced HNSCC non suitable for CT-RT, as compared to the treatment of reference combining cetuximab and RT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 133
• Est. completion date: October 17, 2022
• Est. primary completion date: October 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Written informed consent

2. Age =18 = 80 years.

3. Performance Status ECOG 0-1

4. Histologically confirmed diagnosis of previously untreated locally advanced HNSCC (Stage III, IVa and IVb according to the American Joint Committee on Cancer Staging System) of one or more of the following sites: oral cavity, oropharynx, hypopharynx and larynx

5. Availability of pre-treatment tumour tissue (for biomarker analysis, PD -L1, TILs and immune-monitoring)

6. p16 expression from tumor sample (immunohistochemistry)

7. Recording of the smoking history

8. No viral infection (HIV, Hepatitis B/C)

9. No autoimmune disease

10. No immunodeficiency or immunosuppressive therapy

11. No active CNS disease

12. No interstitial lung disease

13. No active infection

14. Women of child-bearing potential: negative serum pregnancy test at screening and use of appropriate contraception methods from study entry

15. Patients not proposed cisplatin-based chemotherapy because of age, general condition, if medically unfit or patient refusal.

16. Adequate organ laboratory values

17. Health insurance coverage

Exclusion Criteria:

1. Nasopharyngeal, paranasal sinuses, nasal cavity tumours or thyroid cancers;

2. Squamous cell cancer involving cervical neck nodes with unknown primary site;

3. Metastatic disease;

4. Any prior or current treatment for invasive head and neck cancer. This will include but is not limited to: prior tyrosine kinase inhibitors, any monoclonal antibody, prior neoadjuvant therapy, prior surgical resection, or use of any investigational agent;

5. Weight loss of >10% during the last 3 weeks prior the screening visit;

6. Concurrent treatment with any other systemic anti-cancer therapy that is not specified in the protocol;

7. Concomitant treatment with any drug on the prohibited medication list such as live vaccines (for details, see the protocol);

8. History of another malignancy within the last 3 years (exception of in situ carcinoma and skin carcinomas);

9. If female, pregnant or lactating;

10. Significant disease which, in the judgment of the investigator, as a result of the medical interview, physical examinations, or screening investigations would make the patient inappropriate for entry into the trial.

11. Known hypersensitivity reaction to study medication;

12. Any social, personal, medical and/or psychologic factor(s) that could interfere with the observance of the patient to the protocol and/or the follow-up and/or the signature of the informed consent.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Intervention

Drug:
• Pembrolizumab
200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy. Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
• Cetuximab
Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy. Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).

Radiation:
• Radiotherapy
Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).

Locations

Country	Name	City	State
France	Centre Guillaume le conquérant	Le Havre

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Oncologie Radiotherapie Tete et Cou

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Locoregional Control	To compare between the 2 arms the rate of patients achieving Locoregional Control (LRC) at 15 months from the end of radiation therapy	15 months from the end of radiation therapy
Secondary	Progression free survival	Minimum time from randomization to progression/relapse at any site (local, regional or distant) as defined by RECIST 1.1 criteria or to death from any cause. Patients who don't have any of these events are censored at the date of last follow-up.	At 24 months after treatment initiation
Secondary	Locoregional progression and distant metastasis	To estimate the respective contribution of locoregional progression, distant progression and death as first event in the progression-free survival, the cumulative incidences of these three types of events were calculated within a competing risk framework.	At 24 months after treatment initiation
Secondary	Overall survival	Time to death from any cause measured from randomization.	At 24 months after treatment initiation
Secondary	Acute adverse events	According to NCI-CTCAE version 4, the maximal grade of each toxicity observed during immune-radiotherapy will be used. All grades of toxicity will be tabulated by type of toxicity and by treatment arm.	At 24 months after treatment initiation
Secondary	Delayed toxicity According to RTOG late toxicity scale	According to RTOG late toxicity scale	At 24 months after treatment initiation
Secondary	Duration of the feeding tube dependence	It will be presented by treatment arm and analysed by Student t-test.	At 24 months after treatment initiation
Secondary	Compliance to Pembrolizumab and Cetuximab	Insufficient compliance to cetuximab or Pembrolizumab is defined as a patient receiving less than 75% of the planned dose, even if the dose reduction is due to toxicity	At 24 months after treatment initiation
Secondary	Health related quality of life (QL)	Assessment by EORTC QLQ-C30 and H&N35 questionnaires	At 24 months after treatment initiation
Secondary	Impact of p16 / HPV tumor status on the efficacy of the 2 regimens in patients with oropharyngeal initial tumor	Assessment by CISH DNA method	At 24 months after treatment initiation